Synovex Corporation Patent applications |
Patent application number | Title | Published |
20130189251 | HUMANIZED ANTIBODIES TARGETING THE EC1 DOMAIN OF CADHERIN-11 AND RELATED COMPOSITIONS AND METHODS - The present invention relates to humanized antibodies that specifically bind an EC1 domain of a mammalian Cadherin-11 protein and compositions (e.g., pharmaceutical compositions) comprising such antibodies. The invention also relates to methods for treating Cadherin-11-mediated disorders in a mammalian subject by administering a therapeutically effective amount of a humanized antibody of the invention. Cadherin-11-mediated disorders suitable for treatment by the methods of the invention include inflammatory disorders (e.g., inflammatory joint disorders, such as rheumatoid arthritis), fibrosis and cancer. | 07-25-2013 |
20110045003 | CADHERIN-11 ANTAGONISTS AND METHODS FOR THE TREATMENT OF INFLAMMATORY JOINT DISORDERS - The present invention relates to Cadherin-11 antagonists and compositions comprising Cadherin-11 antagonists. The invention also relates to methods for treating inflammatory joint disorders, such as rheumatoid arthritis, in a mammalian subject by administering a therapeutically effective amount of a Cadherin-11 antagonist. | 02-24-2011 |
20110008323 | Cadherin-11 EC1 Domain Antagonists for Treating Inflammatory Joint Disorders - The present invention relates to Cadherin-11 antagonists and compositions comprising Cadherin-11 antagonists. The invention also relates to methods for treating inflammatory joint disorders, such as rheumaotid arthritis, in a mammalian subject by administering a therapeutically effective amount of a Cadherin-11 antagonist. | 01-13-2011 |
20090253200 | CADHERIN-11 ANTAGONISTS AND METHODS FOR THE TREATMENT OF INFLAMMATORY JOINT DISORDERS - The present invention relates to Cadherin-11 antagonists and compositions comprising Cadherin-11 antagonists. The invention also relates to methods for treating inflammatory joint disorders, such as rheumatoid arthritis, in a mammalian subject by administering a therapeutically effective amount of a Cadherin-11 antagonist. | 10-08-2009 |